Botulinum Toxin Type A was first approved by the FDA in December of 1989 to treat two eye muscle disorders. BOTOX^® Botulinum Toxin Type A purified neurotoxin complex, (BOTOX^®), is Allergan's brand of Botulinum Toxin Type A. BOTOX^® was approved by the FDA in April, 2002 for treatment of frown lines between the eyebrows. To date, BOTOX^® has been used to treat over one-half million patients and is approved by the health ministries of at least seventy countries.

BOTOX^® is an injectable treatment derived from a purified protein. Smiling, frowning, and raising your eyebrows many times a day over a period of years can cause crow's feet, frown lines between the eyes and horizontal wrinkles on your forehead. BOTOX^® smoothes out lines by preventing involved muscles from contracting into a wrinkle. Injecting tiny amounts of BOTOX^® into the muscles that cause these lines can reduce the wrinkled appearance within a day or two.

BOTOX^® is administered in several injections of purified protein directly into the affected area. BOTOX^® works by blocking nerve impulses. This results in the relaxation of the contraction of the muscles. After just one ten-minute treatment, and as early as one to two days following treatment with BOTOX^®, the wrinkles will appear diminished. The effects of a BOTOX^® treatment usually last up to four months. Individual results may vary.